The article reiterates a 'Strong Buy' rating for Alcon with a price target of $118, indicating positive sentiment. The minor guidance cut is not seen as structural, and new product launches along with growth in the surgical business are expected to drive significant growth, supporting a positive short-term impact on the stock price.